Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable

Area of Science:

• Oncology
• Nanomedicine
• Biotechnology

Background:

• Glioblastoma (GBM) is an aggressive primary brain tumor with limited treatment options due to its heterogeneous nature, an immunosuppressive tumor microenvironment (TME), and the blood-brain barrier (BBB) hindering drug delivery to the central nervous system (CNS).
• Current therapeutic strategies for GBM face significant challenges, restricting patient survival and treatment efficacy.
• Nanotechnology and nanocarrier-based drug delivery present a promising avenue to overcome these obstacles in GBM treatment.

Purpose of the Study:

• To review the current status and innovative designs of nanotechnology-based combination therapies for glioblastoma (GBM).
• To highlight the potential of nanocarriers in enhancing drug delivery across the blood-brain barrier (BBB) and mitigating the immunosuppressive tumor microenvironment (TME).
• To explore various nano-based combination treatment modalities including nano-chemotherapy, nano-chemotherapy-radiation, nano-chemotherapy-phototherapy, and nano-chemotherapy-immunotherapy for GBM.

Main Methods:

• Literature review focusing on recent advancements in nanotechnology applications for glioblastoma (GBM) treatment.
• Analysis of studies investigating combination therapies enhanced by nanocarriers.
• Synthesis of information on nano-chemotherapy, nano-chemotherapy-radiation, nano-chemotherapy-phototherapy, and nano-chemotherapy-immunotherapy strategies.

Main Results:

• Combination therapies demonstrate superior efficacy compared to monotherapies in combating glioblastoma (GBM).
• Nanotechnology-based delivery systems significantly enhance the effectiveness of combination treatments by improving drug targeting and overcoming biological barriers like the TME and BBB.
• Various nano-formulations are being developed to integrate chemotherapy with radiation, phototherapy, and immunotherapy for synergistic effects against GBM.

Conclusions:

• Nanotechnology-based combination therapies hold significant promise for improving treatment outcomes in glioblastoma (GBM).
• Overcoming the TME and BBB through nanocarrier-mediated delivery is crucial for effective GBM treatment.
• Further research into innovative nano-designs for combination therapies is essential to advance GBM treatment strategies.